- Document Number:
20120130699
- Appl. No:
12/931469
- Application Filed:
February 01, 2011
- Abstract:
Industrial Application: This invention may be used in human and veterinary medicine for the design (creation and synthesis) of therapeutic and preventive drugs that are effective for the treatment of oncological and viral human and animal illnesses and for the design of new medicines. Summary of the Invention: A new method of design and synthesis of therapeutic and preventive drugs in which a biopolymer target (protein, DNA, RNA, or a mixture of these) is used, and in the capacity of a ligand, the same biopolymer target is used, which is cut into oligomer fragments (nucleases, synthetic nucleases, and proteases); the fragments are modified through changing their charges to the opposite charge (acylation of anhydrides of dicarbonate acids or alkylation with halogen-carbonic acids). Also in the capacity of a ligand, the same biopolymer target is used, which is modified by partially changing the molecules' charges to the opposite with the creation of supramolecular biopolymer assemblies. We used supramolecule assemblies made from oligomers that were products of the hydrolysis of biopolymers, but with a change of the charge of the molecules to the opposite charge, as well as the partial change of the charges of the target biopolymers. Technical Result: A method of molecular design and synthesis of new, unique therapeutic and preventive drugs based on self-organizing systems. The application of the method will allow a significant cut to expenditures on the design and synthesis of new drugs, expand the activity spectra of existing protein gene-engineered drugs, and create new classes of dynamic therapeutic and preventive drugs that self-adapt to the organism and target.
- Inventors:
Martynov, Artur (Kharkov, UA); Farber, Boris S. (Brooklyn, NY, US); Farber, Sonya Sophya (New York, NY, US)
- Claim:
1. A method of molecular design and synthesis of therapeutic and preventive drugs in which a biopolymer target is used, including the determination of a target for the drug; the study, with the help of methods of molecular computer modeling, of the interactions are studied between the target and several models of drug ligands and the synthesis of the most active drug possible, distinguished by the fact that in the capacity of a ligand, the same biopolymer target is used, which is cut into oligomer fragments; the fragments are modified through changing their charges to the opposite charge with the creation of supramolecular assemblies that are used as an active drug.
- Claim:
2. The method according to claim 1, with the difference that protein is used as the biopolymer target.
- Claim:
3. The method according to claim 1, with the difference that a mixture of proteins is used as the biopolymer target.
- Claim:
4. The method according to claim 1, with the difference that milk is used as the biopolymer target.
- Claim:
5. The method according to claim 1, with the difference that egg white is used as the biopolymer target.
- Claim:
6. The method according to claim 1, with the difference that DNA is used as the biopolymer target.
- Claim:
7. The method according to claim 1, with the difference that RNA is used as the biopolymer target.
- Claim:
8. The method according to claim 1, with the difference that a mixture of DNA and RNA proteins and their combinations is used as the biopolymer target.
- Claim:
9. The method according to claim 1, with the difference that the biopolymer target is cut into fragments using proteases.
- Claim:
10. The method according to claim 1, with the difference that the biopolymer target is cut into fragments using nucleases.
- Claim:
11. The method according to claim 1, with the difference that the biopolymer target is cut into fragments using synthetic nucleases.
- Claim:
12. The method according to claim 1, with the difference that the charges of oligomer fragments of the biopolymer target are changed to their opposites through acylation.
- Claim:
13. The method according to claim 9, with the difference that trypsin is used in the capacity of a protease.
- Claim:
14. The method according to claim 1, with the difference that a partial change of the biopolymer target charge to its opposite is effected through acylation.
- Claim:
15. The method according to claim 1, with the difference that a partial change of the biopolymer target charge to its opposite is effected through acylation.
- Claim:
16. The method according to claim 1, with the difference that from 0.5 to 100% of the biopolymer target charge is changed to its opposite.
- Claim:
17. The method according to any one of claims 1, with the difference that acylation is caused by anhydrides of carboxylic and polycarboxylic acids.
- Claim:
18. The method according to any one of claims 1, with the difference that acylation is caused by halogen-producing carboxylic and polycarboxylic acids.
- Claim:
19. A method of molecular design and synthesis of therapeutic and preventive drugs that includes determination of the target of the drug's action; with the help of methods of molecular computer modeling, the interactions are studied between the target and several models of drug ligands and the synthesis of the most active drug possible, distinguished by the fact that the same biopolymer target is used, which is modified by partially changing the charge of the molecule to the opposite sign with the creation of supramolecular assemblies that are used as an active drug.
- Claim:
20. The method according to claim 19, with the difference that protein is used as the biopolymer target.
- Claim:
21. The method according to claim 19, with the difference that a mixture of proteins is used as the biopolymer target.
- Claim:
22. The method according to claim 19, with the difference that milk is used as the biopolymer target.
- Claim:
23. The method according to claim 19, with the difference that egg white is used as the biopolymer target.
- Claim:
24. The method according to claim 19, with the difference that DNA is used as the biopolymer target.
- Claim:
25. The method according to claim 19, with the difference that RNA is used as the biopolymer target.
- Claim:
26. The method according to claim 19, with the difference that a mixture of DNA and RNA proteins and their combinations is used as the biopolymer target.
- Claim:
27. The method according to claim 19, with the difference that the biopolymer target is cut into fragments using proteases.
- Claim:
28. The method according to claim 19, with the difference that the biopolymer target is cut into fragments using nucleases.
- Claim:
29. The method according to claim 19, with the difference that the biopolymer target is cut into fragments using synthetic nucleases.
- Claim:
30. The method according to claim 19, with the difference that the charges of oligomer fragments of the biopolymer target are changed to their opposites through acylation.
- Claim:
31. The method according to claim 27, with the difference that trypsin is used in the capacity of a protease.
- Claim:
32. The method according to claim 19, with the difference that a partial change of the biopolymer target charge to its opposite is effected through acylation.
- Claim:
33. The method according to claim 19, with the difference that a partial change of the biopolymer target charge to its opposite is effected through acylation.
- Claim:
34. The method according to claim 19, with the difference that from 0.5 to 100% of the biopolymer target charge is changed to its opposite.
- Claim:
35. The method according to claim 19, with the difference that acylation is caused by anhydrides of carboxylic and polycarboxylic acids.
- Claim:
36. The method according to claim 19, with the difference that acylation is caused by halogen-producing carboxylic and polycarboxylic acids.
- Current U.S. Class:
703/12
- Current International Class:
06
- Accession Number:
edspap.20120130699
Processing Request
No Comments.